Clinical Trial

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non-Hodgkin lymphoma
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-08-12; most recent amendment 2026-07-22.
Status change: Not Yet Recruiting → Recruiting 2025-08-18
Trial Details
NCT Number NCT07121946
Lead Sponsor LTZ Therapeutics, Inc.
Conditions Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL)
Enrollment 42 participants
Start Date 2026-01-29
Primary Completion 2028-02 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-24